瑞士抗VEGF疗法在新生血管性年龄相关性黄斑变性和糖尿病性黄斑水肿中的成本最小化分析

数据集获取（Figshare）

• 源站标题：Cost-minimisation analysis of anti-VEGF therapies in neovascular age-related macular degeneration and diabetic macular oedema in Switzerland
• DOI：10.6084/m9.figshare.29616978.v1
• 发布日期：2025-07-22
• 文件数：4 个
• 文件总体积：134.67 KB
• 源站页面：https://tandf.figshare.com/articles/dataset/Cost-minimisation_analysis_of_anti-VEGF_therapies_in_neovascular_age-related_macular_degeneration_and_diabetic_macular_oedema_in_Switzerland/29616978

命令行下载

curl -L -o "ijme_a_2536420_sm1953.docx" "https://ndownloader.figshare.com/files/56446065"
curl -L -o "ijme_a_2536420_sm1952.docx" "https://ndownloader.figshare.com/files/56446068"
curl -L -o "ijme_a_2536420_sm1951.docx" "https://ndownloader.figshare.com/files/56446071"
curl -L -o "ijme_a_2536420_sm1950.xlsx" "https://ndownloader.figshare.com/files/56446074"

文件清单

• ijme_a_2536420_sm1953.docx（33.32 KB）
• ijme_a_2536420_sm1952.docx（39.97 KB）
• ijme_a_2536420_sm1951.docx（42.13 KB）
• ijme_a_2536420_sm1950.xlsx（19.26 KB）

文件总体积 134.67 KB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

This study compares the direct healthcare costs of anti-VEGF therapies, including treat-and-extend (T&E) and other durable regimens, for unilateral neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO) in Switzerland.
An adapted cost-minimisation model estimated healthcare costs over two years for aflibercept 2 mg, aflibercept 8 mg, faricimab, ranibizumab, and ranibizumab biosimilars using clinical trial injection frequencies. Break-even analyses identified the medication prices and injection frequencies required for higher-cost therapies to achieve cost parity with the least expensive options. A one-way sensitivity analysis (OWSA) assessed key drivers of cost outcomes.
Aflibercept 8 mg was estimated to be associated with the lowest treatment costs for both indications (CHF 11,814 for nAMD; CHF 11,242 for DMO). Faricimab (CHF 13,737) and aflibercept 2 mg (CHF 15,243) followed in nAMD and DMO. Ranibizumab and its biosimilars incurred the highest costs: for nAMD, biosimilars ranged from CHF 16,243 to CHF 17,497 and the reference product reached CHF 18,424; for DMO, biosimilars ranged from CHF 18,187 to CHF 19,596, with the reference product at CHF 20,637. Break-even analyses for nAMD showed that prices would need to drop by −22% (faricimab, CHF 644) to −64% (ranibizumab reference, CHF 218) relative to aflibercept 8 mg. For DMO, reductions ranged from −42% (aflibercept 2 mg, CHF 493) to −81% (ranibizumab reference, CHF 114). The OWSA highlighted medication price and injection frequency as primary cost drivers.
This study estimated that the potentially minimized injection frequency of aflibercept 8 mg in a clinical trial regimen may result in the lowest treatment costs for nAMD and DMO, followed by faricimab and aflibercept 2 mg, respectively.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.6084/m9.figshare.29616978.v1（source: https://tandf.figshare.com/articles/dataset/Cost-minimisation_analysis_of_anti-VEGF_therapies_in_neovascular_age-related_macular_degeneration_and_diabetic_macular_oedema_in_Switzerland/29616978）。